Telix is an important strategic partner to the Group. The proceeds will be used to fund the Group’s clinical development plans in areas of unmet need, including projects being carried out in collaboration with Telix. Additionally, as we are working with Telix to develop potential new imaging agents and therapies for diagnosing and treating tumors in the Chinese market, we believe that Telix has the potential to create further value.

In November 2020, the Group made a strategic equity investment of US$25M (equivalent to approximately AU$35M) in via a private placement 20,947,181 fully paid ordinary Telix shares at an issue price of AU$1.69 per share. The Group also holds exclusive development and commercialization rights to Telix’s portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic products in the Greater China market.

This product achieved approximately AUD 783 million in global sales revenue in 2024, representing a yearon-year growth of nearly 56%, which is very encouraging for us. At the same time, the
development of several innovative radiopharmaceutical conjugates (RDCs) by Telix is also
progressing smoothly, including the submission of a biologics licence application for
TLX250-CDx for kidney cancer imaging to the US FDA, which has been accepted and is
under priority review. Therefore, we are very optimistic about its future prospects.
Additionally, as we are working with Telix to develop potential new imaging agents and
therapies for diagnosing and treating tumors in the Chinese market, we believe that Telix has
the potential to create further value. As investors, we are also pleased to have realized our
initial investment vision. We have informed Telix of our intention not to sell our remaining
shares within the next 12 months, demonstrating our confidence in Telix and our continued
commitment to the partnership between the two companies.”